Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Testing phagocytes might better characterize IBD dysbiosis

Key clinical point: Microbiota from phagocytes of the intestinal lamina propria differs from mucosal microbiota.

Major finding: Compared with mucosal microbiota from the same patients, the microbiota of the lamina propria was enriched in Proteobacteria, the “defining phyla” associated with dysbiosis in inflammatory bowel disease.

Study details: 16S ribosomal gene sequencing of lamina propria phagocytes and mucosal microbiota, and innate immune gene expression profiling, of 32 patients with inflammatory bowel disease.

Disclosures: The study was supported by the National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Crohn’s & Colitis Foundation of America, Micky & Madeleine Arison Family Foundation Crohn’s & Colitis Discovery Laboratory, and the Martin Kaiser Chair in Gastroenterology at the University of Miami. The senior investigator disclosed ties to Prometheus, Takeda, Pfizer, AbbVie, Janssen, and several other companies. The other researchers reported having no conflicts of interest.


Dheer R et al. Cell Mol Gastroenterol Hepatol. 2020. doi: 10.1016/j.jcmgh.2019.10.013.